Mohamad Mukhtar - Millennium Pharmacon President Director

SDPC Stock  IDR 144.00  1.00  0.69%   

President

Mr. Mohamad Muhazni bin Mukhtar serves as President Director of PT Millennium Pharmacon International Tbk since October 18, 2012. He obtained American Associate degree from Indiana University in 1988, Bachelor of Business Administration in Management Science from University of Iowa in 1990, MBA from Ohio UniversityUniversiti Teknologi MARA in 1993, and MS in Business Leadership from Newcastle Business School, Northumbria University in 2010. He has worked with London Pacific Insurance Bhd in 1991, Plus Expressway Bhd from 1993 until 1996, Touch and Go Sdn Bhd, Faber Group Bhd and Faber Facilities Sdn Bhd. He is a member of Company Management Risk Committee. since 2012.
Age 46
Tenure 12 years
Professional MarksMBA
Phone62 21 270 85961
Webhttps://www.mpi-indonesia.co.id

Millennium Pharmacon Management Efficiency

The company has return on total asset (ROA) of 0.0342 % which means that it generated a profit of $0.0342 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0938 %, meaning that it generated $0.0938 on every $100 dollars invested by stockholders. Millennium Pharmacon's management efficiency ratios could be used to measure how well Millennium Pharmacon manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.8 B in total debt with debt to equity ratio (D/E) of 257.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Millennium Pharmacon has a current ratio of 1.13, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Millennium Pharmacon until it has trouble settling it off, either with new capital or with free cash flow. So, Millennium Pharmacon's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Millennium Pharmacon sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Millennium to invest in growth at high rates of return. When we think about Millennium Pharmacon's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Gidion HasanUnited Tractors Tbk
46
John GledhillHanjaya Mandala Sampoerna
65
Jahja SetiaatmadjaBank Central Asia
67
Joseph GodongBank Mandiri Persero
56
Agus NoorsantoBank Rakyat Indonesia
54
Kepas ManurungBank Mandiri Persero
N/A
Andrinof ChaniagoBank Rakyat Indonesia
56
Wimboh SantosoBank Mandiri Persero
58
Toni SubariBank Mandiri Persero
59
Charles BendottiHanjaya Mandala Sampoerna
42
Budi SadikinBank Mandiri Persero
50
David NewbiggingUnited Tractors Tbk
43
Imam PutroBank Mandiri Persero
53
Alexandra AskandarBank Mandiri Persero
51
Rico FransBank Mandiri Persero
47
Ventje RahardjoBank Mandiri Persero
62
Hartadi SarwonoBank Mandiri Persero
66
Djony TjondroAstra International Tbk
59
Hexana SasongkoBank Rakyat Indonesia
51
PradjotoBank Negara Indonesia
62
MustaslimahBank Mandiri Persero
52
PT Millennium Pharmacon International Tbk distributes and trades in prescription medicine, non-prescription medicine, food supplements, and medical devices. PT Millennium Pharmacon International Tbk is a subsidiary of Pharmaniaga International Corporation Sdn. Millennium Pharmacon operates under Medical Distribution classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 1092 people. Millennium Pharmacon International (SDPC) is traded on Jakarta Exchange in Indonesia and employs 1,089 people.

Management Performance

Millennium Pharmacon Leadership Team

Elected by the shareholders, the Millennium Pharmacon's board of directors comprises two types of representatives: Millennium Pharmacon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Millennium. The board's role is to monitor Millennium Pharmacon's management team and ensure that shareholders' interests are well served. Millennium Pharmacon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Millennium Pharmacon's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mohamad Hassan, F Director
Glenn Ariff, Unaffiliated Director
Aris, Chairman Audit
Dian Anggreni, Legal and Corporate Secretary
Ernie Hilal, Corporate Secretary
Yungkis Sucandra, Head Unit
Ahmad Bakar, Pres Director
Mohamad Mukhtar, President Director
Morsela, Ma Marketing
Puji Hartono, Head Unit
Nyoman Rai, Independent Commissioner
Dedi Martadiredja, Sr Sales
Ivan Hanafi, Independent Director
Olga Bolang, Co Sec
Noraini Ali, Commissioner
Izzat Othman, President Commissioner, Independent Commissioner
Yuni Arrivani, Deputy Legal
Mohamed Rahman, Commissioner

Millennium Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Millennium Pharmacon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Millennium Pharmacon International. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Millennium Stock analysis

When running Millennium Pharmacon's price analysis, check to measure Millennium Pharmacon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Millennium Pharmacon is operating at the current time. Most of Millennium Pharmacon's value examination focuses on studying past and present price action to predict the probability of Millennium Pharmacon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Millennium Pharmacon's price. Additionally, you may evaluate how the addition of Millennium Pharmacon to your portfolios can decrease your overall portfolio volatility.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Please note, there is a significant difference between Millennium Pharmacon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Millennium Pharmacon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Millennium Pharmacon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.